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CORD BLOOD (CB) APGAR SCORE MAY BE PREDICTIVE OF TRANSPLANT
RELATED MORTALITY (TRM), OVERALL SURVIVAL (OS) AND DISEASE-
FREE SURVIVAL (DFS) FOR PLASMA DEPLETED/REDUCED CB PRODUCTS
Chow, R.1, Wang, B.C.1, Chow, M.1, Chou, D.1, Wu, T.1, Lin, A.2,
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CB potency is important for engraftment potential prediction and
transplantation product selection and Nucleated cell (NC), CD341
cell (CD34), and colony forming unit (CFU) doses have been used to
measure such potency.TNCiswidely used forCB selection; however
its predictive value is not as robust as the progenitor cell measure-
ments. In contrast, CFU andCD34 suffer fromhigh inter-laboratory
coefficient of variance - decreasing their utility as potency measures.
Recently, the Duke Group proposed a CB APGAR scoring system
composed of (a) a Pre-Cryopreserved Score (PCS) reflecting pre-
freeze CFU, CD34, NC, and CB collected volume, as well as a (b)
Composite Score (CS) which combines the PCS score with post-
thaw NC, CD34, CFU and mononuclear cell dose. Based on single,
myeloablative and first (SMF) transplants of largely pediatric patients
performed at Duke and using mostly red cell reduced (RCR) CB, the
PCS and CS scores were shown to be predictive of graft failure, neu-
trophil and platelet engraftment. Subsequently, the CB APGAR
Score was further validated by us recently for engraftment prediction
on a patient population with mostly adults, heavy representation of
minority and international patients, and on both SMF transplants,
and all transplants (All) using plasma depleted/reduced (PDR) CB
products. We next examined if PCS and CS can correlate with re-
lapse, transplant related mortality (TRM), overall (OS) and disease
free survival (DFS) on the SMF patients transplanted with PDR CB
products. The table below shows K-M probabilities of 100-day and
1-Year TRM, 1-Year OS, DFS and relapse for the various PCS and
CS strata that had sufficient sample size. There appears to be no cor-
relation between PCS/CS and relapse; however, both scores appear
to be predictive of TRM,OS andDFS.We conclude that in addition
to its utility as an easy-to-use engraftment prediction tool, the CB
APGAR score may be predictive of TRM, OS and DFS for PDR
CB transplanted for mixed adult and pediatric populations and for
minority and international patients.This observationmay further en-
hance the value of Duke CB APGAR as a reproducible and practical
potency measurement for CB selection by transplant centers.
Table 1. CB APGAR Correlation with TRM, OS and DFS
1-Year 100-DayRelapse TRM 1-Yr TRM 1-Year OS 1-Year DFSPCS <4.25 16.7 ± 15.2% 31.9 ± 10.1% 31.9 ± 10.1% 51.6 ± 10.6% 48.9 ± 13.6%PCS $4.25
- <5.514.3 ± 13.2% No Events 11.6 ± 7.8% 79.3 ± 9.3% 71.8 ± 14.0%PCS $5.5
- <7.75No Events No Events No Events 92.3 ± 7.4% 100%CS Score
< 13.512.5 ± 11.7% 25.4 ± 9.9% 31.1 ± 10.7% 51.3 ± 11.1% 51.2 ± 14.1%CS Score








T-RAPA CELL DLI SAFELY BALANCES Th1/Th2 CYTOKINE ACTIVATION
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We recently reported that pre-emptive DLI with donor T-rapa
cells safely promotes alloengraftment after low-intensity alloge-
neic HCT (ASH, 2010; multi-center clinical trial NCT
0074490). T-rapa cells were manufactured ex vivo using purified
CD41 T cells, rapamycin, co-stimulation, and IL-4. T-rapa clin-
ical products contained minimal Treg cells and secreted both Th1
(IFN-g, IL-2) and Th2 cytokines (IL-4, IL-5, IL-10, and IL-13).
On one protocol arm, refractory hematologic malignancy patients
(n 5 40) received EPOCH-FR induction chemotherapy, low-dose
fludarabine/cyclophosphamide (Cy) preparative chemotherapy
(total Cy dose, 1200 mg/m2), T cell-replete mobilized allografts,
and GVHD prophylaxis of cyclosporine and short-course siroli-
mus (until day 114 post-HCT). T-rapa cells were administered
at day 114 (2.5  107 T-rapa cells/kg). This transplant approach
was safe, as there was: (1) no engraftment syndrome (0/40 cases);
(2) a low rate of grade II-IV acute GVHD (4/40); and (3) no
transplant-related mortality (0/40). Complete remission has
been sustained in 37.5% (15/40) of patients. Median survival is
28.5 months; 24-month survival probability is 64.4%. T-rapa
DLI was associated with conversion of mixed chimerism: median
donor CD31 T cell chimerism values at days 114, 128, and
1100 were 61%, 89%, and 93%, respectively. The capacity of
T-rapa DLI to safely promote alloengraftment suggested that
a balanced pattern of Th1/Th2-type cytokines may have been ac-
tivated post-HCT. To assess this, post-HCT peripheral blood T
cells were co-stimulated; supernatants were then tested for cyto-
kine content.
Table 1. Day +14 Post-HCT DLI With T-rapa Cells Yields
Balanced type I/type II Cytokine Secretion
Prior to T-rapa Infusion After T-rapa Infusion
T Cell
Supernatant Day +7 Day +14 Day +28 Day +50IFN-g 957 ± 487 246 ± 114 976 ± 722 1165 ± 550
IL-2 2058 ± 1334 124 ± 29 1601 ± 1093 706 ± 214
TNF-a 7617 ± 6475 310 ± 112 413 ± 204 438 ± 118
IL-17 33 ± 1 < 1 108 ± 108 42 ± 36IL-4 4 ± 4 2 ± 2 20 ± 15 8 ± 5
IL-5 105 ± 10 2 ± 1 157 ± 103 100 ± 57
IL-10 5 ± 2 7 ± 1 24 ± 12 18 ± 7
IL-13 22 ± 15 14 ± 7 218 ± 145 167 ± 57Ex vivo generated donor T-rapa cells were administered as a pre-emp-
tive DLI at day +14 post-HCT. Post-HCT mononuclear cells were
harvested at days +7, +14, +28 (6 2 days) and day +50 (6 4 days)
post-HCT; cells were subjected to CD3, CD28 co-stimulation, and
24 h supernatants were tested for cytokine content by multi-plex assay.
Values shown are mean6 SEM, in pg/ml. For each measurement, values
were available on n 5 29 to n 5 30 T-rapa cell recipients.
Day17 T cells secreted large quantities (ng/ml range) of Th1 cyto-
kines IFN-g and IL-2; Th1 cytokine secretion was blunted by day
114 but increased again after T-rapa DLI. TNF-a secretion was
prominent at day 17, normalized prior to T-rapa DLI, and was
not increased post-DLI. IL-17 was undetectable at day 114 and
was moderately increased after T-rapa DLI. Early post-HCT, Th2
cytokine secretion was modest, particularly at day114; mean values
for IL-4, IL-5, and IL-13 secretion were increased by at least one-log
at day128 and were generally increased at day150.Mean values for
IL-10 were modestly higher after T-rapa DLI. In conclusion, pre-
emptive DLI with T-rapa cells was associated with a balanced acti-
vation of both Th1- and Th2-type cytokines that appears favorable
for the safe promotion of alloengraftment after low-intensity host
preparation.
